BA3021-001 A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors.

NCTNCT03504488

A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors.

Associated Conditions

Multiple Tumor Types

Principal Investigator

George Simon

Sponsor

BioAtla LLC